The CYP19A1 gene encodes the steroidogenic enzyme aromatase on chromosome 15q21.2 (OMIM 107910; RefSeq NM_000103.3). It spans over 123 kb and consists of 9 coding exons (spanning over 30 kb, exons 2-10). For the *CYP19A1* gene, a large number of alternative first exons and 9 different transcriptional start sites with individual promoters have been described \[[@CIT0001], [@CIT0002]\]. Several tissues use their specific promoters leading to a very complex tissue-specific regulation of CYP19A1 expression. Metabolic activities of aromatase include the biosynthesis of estrone from androstenedione, estriol from 16-hydroxytestosterone, and 17β-estradiol from testosterone \[[@CIT0003]\]. Of these, androstenedione and testosterone are the common physiological steroid substrates of aromatase \[[@CIT0003]\]. Recently 16β-OH-androstenedione was also reported to be a substrate for aromatase \[[@CIT0006]\]. Although the human ovary is the principal site of estrogen production, even the testis produces estrogens, and extragonadal synthesis occurs from circulating C19 steroids in bone, breast, brain, adipose, and other tissues through aromatase expressed in these tissues. The role of aromatase and thus estrogens for human biology is best illustrated in disease states, both deficiency and excess.

Aromatase deficiency (OMIM 613546) is a rare, autosomal recessive disorder that was first described in 1991 by Shozu et al in a mother who experienced virilisation during pregnancy due to a 46,XX fetus with aromatase deficiency that presented with severe virilization of the external genitalia at birth \[[@CIT0007]\]. Meanwhile, about 50 cases of aromatase deficiency due to variants in *CYP19A1* have been reported, both in female and male patients ([Table 1](#T1){ref-type="table"} and [Fig.1](#F1){ref-type="fig"}) \[[@CIT0007]\]. During pregnancy, aromatase deficiency of the fetus typically manifests in the pregnant mother by progressive virilization due to the inability of the placenta to aromatize androgens derived from the fetal adrenals. These androgens also virilize the 46,XX fetus. During infancy and childhood, aromatase deficiency may go unnoticed, although, in some girls, abdominal problems may be seen due to ovarian cysts caused by a lack of feedback regulation of estrogens to the hypothalamic-pituitary-gonadal axis \[[@CIT0034]\]. At puberty, girls without aromatase activity are not able to produce estrogens from androgen precursors for pubertal development, for example, breast and uterine development. Young men with aromatase deficiency usually present in the second decade of life with low bone mass and unfused epiphyses leading to persistent growth into adulthood with extremely tall stature \[[@CIT0043]\]. In addition, aromatase deficiency is reported to cause disturbances of the lipid profile and insulin sensitivity (eg, metabolic syndrome), and it may also cause male infertility and affect bone quality.

###### 

Summary of all reported human CYP19A1/aromatase mutations and their characteristics

  No. of patients   Familial   Consanguinity   Mutation Allele 1                                           Mutation Allele 2                                           Karyotype         Sex of rearing   Age at Presentation      Phenotype                                                                                                                                                                                                                                                                                                                                                              Virilization of Baby at Birth         Virilization of Mother   Spontaneous Puberty           Ovary/Testis Phenotype                                                                                                                                                                                                                                                     Functional Testing                                 Ref.
  ----------------- ---------- --------------- ----------------------------------------------------------- ----------------------------------------------------------- ----------------- ---------------- ------------------------ ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ------------------------------------- ------------------------ ----------------------------- -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- -------------------------------------------------- -----------------
  2                 Yes        NK              M85R                                                        c.629-2G\>A                                                 46,XX             F                Birth                    Ambiguous genitalia at birth, puberty absent and bone age delayed, virilizing signs at pubertal age                                                                                                                                                                                                                                                                    Yes                                   NK                       NK                            NK                                                                                                                                                                                                                                                                         M85R: no activity                                  \(8\)
  2                 Yes        Likely          R115X                                                       R115X                                                       46,XX             M + F            14/8                     P1 (M): At 14 y, undescended testes and hypospadias, presence of ovaries with cysts and small uterus. P2 (F): At 8 y, 1 cm phallus, 2 urogenital openings, pubic pilosity                                                                                                                                                                                              Yes (Prader III in P1 and II in P2)   No                       Yes                           Histo P1: ovarian follicle cysts                                                                                                                                                                                                                                           ND                                                 \(9\)
  2                 Yes        Yes             W141X                                                       P1: W141X; P2: missing allele/deletion                      46,XX             F                2/5                      Hypertrophic clitoris and prepuce with single urogenital opening; low estradiol, elevated LH and FSH                                                                                                                                                                                                                                                                   Yes (Prader IV)                       Yes                      No                            Normal at presentation                                                                                                                                                                                                                                                     ND                                                 \(10\)
  2                 No         No              E210K                                                       E210K                                                       46,XX             F                Birth                    P1: Ambiguous genitalia at birth, spontaneous pubertal development Tanner 4 with virilization signs; menarche at 12 y. P3: Clitorial enlargement with complete labial fusion and urogenital sinus with single phalloscrotal opening; gonads nonpalpable. Spontaneous puberty starting at 9 y, Tanner 3 at 12 y with signs of virilization and elevated gonadotropins   Yes (Prader II in P1; IV in P3)       No                       Yes                           Multiple cysts in both ovaries at age 18 y (P1) and at 9 y (P3)                                                                                                                                                                                                            ND                                                 \(11\)
  1                 No         No              E210K                                                       E210K                                                       46,XY             M                25                       29 y, tall, eunuchoid habitus, cryptorchidism, bone pain, metabolic syndrome                                                                                                                                                                                                                                                                                           NA                                    NK                       Yes                           Histo: hypotrophic seminiferous tubules with mature Sertoli cells. Germ cell depletion without spermatogenic development. Scarce, mature Leydig cells in small groups.                                                                                                     ND                                                 \(12\)
  1                 No         No              E210K                                                       c.1235delA                                                  46,XX             F                Birth                    Ambiguous genitalia and virilization (Prader V), PCOS in childhood; spontaneous breast development at age 8 y                                                                                                                                                                                                                                                          Yes (Prader V)                        Yes                      Yes (partial)                 Large ovarian follicles at 5 mo; Histo: normal stroma, numerous follicles. At 7.7 y: increased size of uterus with multiple ovarian cysts                                                                                                                                  c.1235delA: no activity                            \(11\) (13- 15)
  1                 No         No              E210K                                                       Y81C                                                        46,XX             M to F           Birth                    Phallic enlargement, hypospadias, nonpalpable gonads. Delayed bone age at 6 y                                                                                                                                                                                                                                                                                          Yes (Prader IV)                       Yes                      NA                            Bilateral ovaries with cysts                                                                                                                                                                                                                                               ND                                                 \(11\)
  1                 No         No              R192C                                                       R192C                                                       46,XX             F                Birth                    Ambiguous genitalia, 2 cm phallus                                                                                                                                                                                                                                                                                                                                      Yes (Prader IV)                       Yes                      NA                            Normal by ultrasound at years 3                                                                                                                                                                                                                                            ND                                                 \(11\)
  1                 No         No              R192C                                                       R457X                                                       46,XX             F                Birth                    Ambiguous genitalia, 1 cm phallus and complete labial fusion. Single phalloscrotal opening. No gonads palpable.                                                                                                                                                                                                                                                        Yes                                   No                       Yes                           At 10 y, enlarged ovaries by ultrasound                                                                                                                                                                                                                                    ND                                                 \(11\)
  2                 Yes        Yes             R192H                                                       R192H                                                       46,XX and 46,XY   F + M            F at birth; M at 15 mo   F: Clitoral hypertrophy and labial fusion; M: hypospadia and cryptorchidism                                                                                                                                                                                                                                                                                            F: yes (Prader IV)                    No                       NK                            Histo of ovary at 1 year: normal.                                                                                                                                                                                                                                          19% of WT                                          \(1\)
  1                 No         Yes             R365Q                                                       R365Q                                                       46,XY             M                28                       28 y, continuous growth and unfused epiphysis, infertility, skeletal pain, metabolic syndrome                                                                                                                                                                                                                                                                          NA                                    NK                       Yes                           Histo: hypospermatogenesis and germ cell arrest                                                                                                                                                                                                                            0.4% of WT                                         \(16\)
  1                 No         Likely          V370M                                                       V370M                                                       46,XX             F                Birth                    Ambiguous genitalia (small phallic structure without hypospadias); not palpable gonads. Urogenital sinus                                                                                                                                                                                                                                                               Yes (Prader V)                        Yes                      NA                            Ovaries not visualized at birth                                                                                                                                                                                                                                            ND                                                 \(17\)
  2                 Yes        Yes             R375C                                                       R375C                                                       46,XX and 46,XY   F + M            Birth                    P1, 46,XX, F, 28 y: DSD at birth, sexual infantilism and virilization, PCOS, tall stature. P2, 46,XY, M, 24 y: tall, osteopenia, delayed bone maturation, eunuchoid, macroorchidism                                                                                                                                                                                    Yes (P1)                              Yes                      No in P1 (F), yes in P2 (M)   Histo: ovaries with PCOS phenotype                                                                                                                                                                                                                                         0.2% of WT                                         \(18\)
  2                 Yes        Yes             R375H                                                       R375H                                                       46,XY             M                27                       Bone pain and recurrent forearm fractures, progressive overgrowth                                                                                                                                                                                                                                                                                                      NA                                    NK                       Yes                           Borderline sperm count and motility                                                                                                                                                                                                                                        ND                                                 \(19\)
  1                 No         No              R375H                                                       M127R                                                       46,XY             M                25                       Continuing linear growth, eunuchoid body habitus, adiposity, and diffuse bone pain                                                                                                                                                                                                                                                                                     NA                                    NK                       Yes                           Histo: hypospermatogenesis                                                                                                                                                                                                                                                 R375H: 7% of WT; M127R: 0%                         \(20\)
  1                 No         No              R435C                                                       R435C                                                       46,XX             F                Birth                    Ambiguous genitalia; sexual infantilism, PCO                                                                                                                                                                                                                                                                                                                           Yes (Prader IV)                       Yes                      Yes, partial                  Bilateral cystic ovaries at age 13.5 y                                                                                                                                                                                                                                     1.5% of WT                                         \(21\)
  2                 Yes        Yes             F234del                                                     F234del                                                     46,XX             M + F            Birth                    P1, m: Ambiguous genitalia (phallic enlargement and hypospadia). Gynecomastia at puberty caused gonadectomy. P2, F: Ambiguous genitalia. 2 cm phallus, partial labial fusion.                                                                                                                                                                                          Yes (Prader IV)                       Yes                      Yes                           Histo: cystic ovaries                                                                                                                                                                                                                                                      19% of WT                                          \(21\)
  1                 Yes        Yes             c.452-621-c.628 + 803del                                    c.452-621-c.628 + 803del                                    46,XX             F                Birth                    Labial fusion, excess of clitoral skin                                                                                                                                                                                                                                                                                                                                 Yes                                   Yes                      No                            Small ovaries observed with MRI                                                                                                                                                                                                                                            0%                                                 \(21\)
  1                 No         NK              C437Y                                                       R435C                                                       46,XX             F                Birth                    Ambiguous genitalia at birth; 14 y: primary amenorrhea, no breast development, enlarged clitoris, pubic hair Tanner stage III, sexual infantilism, PCO                                                                                                                                                                                                                 Yes                                   Only acne                No                            Multiple bilateral cysts                                                                                                                                                                                                                                                   C437Y: 0% of WT R435C: 1.1% of WT                  (22, 23)
  1                 No         No              L451P                                                       Y81C                                                        46,XY             M                24                       Eunuchoid proportions, bilateral genua valga, incomplete fused epiphyses, osteopenia                                                                                                                                                                                                                                                                                   NA                                    No                       Yes                           Testes of normal size and consistency                                                                                                                                                                                                                                      L451P: 3.1% of WT Y81C:14.3% of WT                 \(24\)
  1                 NK         NK              R457X                                                       R457X                                                       46,XX             F                NK                       F, virilization                                                                                                                                                                                                                                                                                                                                                        Yes                                   NK                       NK                            NK                                                                                                                                                                                                                                                                         ND                                                 \(25\)
  1                 No         NK              N411S                                                       c.--41C\>T                                                  46,XX             F                Birth                    At birth ambiguous genitalia, clitoral hypertrophy, thin dividing wall between urethral opening and a normal vaginal introitus with a hymen altus                                                                                                                                                                                                                      Yes                                   Yes                      NA                            Normal by ultrasound                                                                                                                                                                                                                                                       N411S: 0% of WT c.-41C\>T: 50% of WT               \(26\)
  1                 No         Yes             c.629-1453_744- 486_del                                     c.629- 1453_744- 486_del                                    46,XX             M + F            Birth                    At 1 mo: ambiguous genitalia, gonads not palpable, phallus 1 cm, uterus by ultrasound                                                                                                                                                                                                                                                                                  Yes (Prader III)                      No                       NA                            Small ovaries by ultrasound                                                                                                                                                                                                                                                ND                                                 \(27\)
  1                 No         Yes             c.1263 + 1G\>T                                              c.1263 + 1G\>T                                              46,XX             M                Birth                    Ambiguous genitalia of unknown cause at birth. At 21 y: undescended testes, hypoplastic scrotum, hypoplastic uterus                                                                                                                                                                                                                                                    Yes (Prader V)                        No                       Abnormal                      Histo: streak gonads                                                                                                                                                                                                                                                       ND                                                 \(28\)
  1                 No         Yes             c.469C_del                                                  c.469C_del                                                  46,XY             M                Birth                    Investigated after birth because of severe maternal virilization. Found low estrogen levels, high androstenedione, normal free testosterone.                                                                                                                                                                                                                           NA                                    Yes                      NA                            Normal                                                                                                                                                                                                                                                                     ND                                                 \(29\)
  1                 No         Yes             c.264G_del                                                  c.1036_1037ins 23bp                                         46,XX             F                Birth                    Ambiguous genitalia, 3 cm clitoromegaly; PCOS later                                                                                                                                                                                                                                                                                                                    Yes (Prader IV)                       Yes                      NA                            Large ovaries with cysts                                                                                                                                                                                                                                                   c.264G_del \< 0.3% of WT; 23bp_del \< 0.3% of WT   \(30\)
  1                 No         Yes             Ala306_Ser314\_ dup                                         Ala306\_ Ser314_dup (likely)                                46,XX             F                Birth                    At birth ambiguous genitalia. Lack of pubertal development. Streak ovaries. At 32 y, osteopenia and fracture, tall stature, central obesity, borderline hypertension, impaired fasting glucose                                                                                                                                                                         Yes (Prader III)                      NK                       No                            Streak ovaries                                                                                                                                                                                                                                                             ND                                                 \(31\)
  1                 No         No              c.1263 + 5G\>A                                              c.1263 + 5G\>A                                              46,XX             F                4                        At 4, labioscrotal fusion, 1.5 cm clitoromegaly, perineal urethra. At 13.5 y, delayed bone age, small uterus, follicular cysts in ovaries.                                                                                                                                                                                                                             Yes                                   No                       Abnormal (B1, P4)             PCOS                                                                                                                                                                                                                                                                       ND                                                 (32, 42)
  1                 No         Yes             c.743 + 2T\>C                                               c.743 + 2T\>C                                               46,XX             F                Birth                    At birth: ambiguous genitalia, enlarged phallus, gonads not palpable                                                                                                                                                                                                                                                                                                   Yes (Prader IV-V)                     Yes                      NA                            ND                                                                                                                                                                                                                                                                         0.3% of WT                                         (7, 33)
  1                 No         No              V445X                                                       c.296 + 1G\>A                                               46,XX             F                Birth                    At birth: masculine- appearing external genitalia, enlarged phallus, complete fusion of posterior labioscrotal folds                                                                                                                                                                                                                                                   Yes (Prader V)                        Yes                      Yes (Tanner 4)                At birth: slightly enlarged ovaries. At 2 y: enlarged ovaries with several cysts, fallopian tubes and uterus normal in appearance, histopathology showed many normal-appearing large tertiary follicles with an oocyte within a cumulus oophorus projecting into antrum.   ND                                                 (34, 35)
  2                 Yes        Yes             c.469C_del                                                  c.469C_del                                                  46,XY and 46,XX   M + F            16 (M                    P1 (M): 16 y, no gynecomastia or other abnormalities, open epiphyses, congenital hearing loss of 85%, delayed bone age                                                                                                                                                                                                                                                 NA and NK (F)                         No                       M: yes and F: no              Normal by clinical exam                                                                                                                                                                                                                                                    ND                                                 \(36\)
  1                 No         Yes             c.629-3C\>A-- frameshift and stop codon 8 nt after exon 5   c.629-3C\>A-- frameshift and stop codon 8 nt after exon 5   46,XY             M                27                       Normal sex characteristics, spontaneous erections sufficient for intercourse, genua valga, kyphoscoliosis, pectus carinatus. Retarded bone maturation. Abnormal glucose and lipid metabolism.                                                                                                                                                                          NA                                    Yes                      Yes                           Below threshold sperm count (1 mL/ mL), 100% immotile spermatozoa. Oligoazoospermia                                                                                                                                                                                        ND                                                 \(37\)
  1                 No         NK              c.311-334_del                                               c.1263 + 1G\>T → Y361X                                      46,XY             M                27                       At 27 y, height 193 cm, eunuchoid, unfused epiphyses, osteopenia, increase fasting insulin, mild astenozoospermia and history of right cryptorchidism                                                                                                                                                                                                                  NA                                    NK                       Yes                           History of cryptorchidism. Borderline FSH and inhibin B at age 27 y                                                                                                                                                                                                        ND                                                 \(38\)
  1                 No         Yes             c.744-2A\>G                                                 c.744-2A\>G                                                 46,XX             F                Birth                    Ambiguous genitalia at birth; 19 mo: gonads not palpable, penis-like phallus 1.5 cm, single penoscrotal urethral opening, labioscrotal fusion defect                                                                                                                                                                                                                   Yes (Prader IV)                       Yes                      NA                            Very small ovaries by ultrasound                                                                                                                                                                                                                                           ND                                                 \(39\)
  1                 NK         NK              c.1058insT                                                  c.1058insT                                                  46,XY             M                26                       190 cm tall, hypertension, hyperuricemia, hypercholesterolemia                                                                                                                                                                                                                                                                                                         NA                                    NK                       Yes                           NK                                                                                                                                                                                                                                                                         ND                                                 \(40\)
  3                 Yes        Yes             c.568insC → L190P leading to S199X                          c.568insC → L190P leading to S199X                          46,XX             F                Birth                    Clitoromegaly, partial to complete labial fusion                                                                                                                                                                                                                                                                                                                       Yes (Prader II-III)                   Yes                      NA                            Hypoplastic ovaries by imaging studies                                                                                                                                                                                                                                     ND                                                 \(41\)

Abbreviations: DSD, disorder of sex development; F, female; FSH, follicle-stimulating hormone; LH, luteinizing hormone; M, male; MRI, magnetic resonance imaging; NA, not applicable; ND, not determined; NK, not known; P1, patient 1; P2, patient 2 etc; PCOS, polycystic ovary syndrome; WT, wild-type.

![Localization of reported *CYP19A1* variants. The coding exons 2 to 10 and the alternative exon I.1 of the aromatase *CYP19A1* gene are shown.](bvaa030f0001){#F1}

Aromatase excess (OMIM 139300) has been found in a few, mostly familial cases of gynecomastia associated with accelerated growth and bone maturation due to excessive peripheral estrogen production. The main causes of aromatase excess include chromosomal rearrangements altering regulatory elements of the *CYP19A1* gene expression or a higher expression of an alternative first exon enhancing *CYP19A1* transcription \[[@CIT0044], [@CIT0045]\]. By contrast, aromatase deficiency is almost exclusively caused by variants altering the coding sequence of the *CYP19A1* gene, such as point mutations, deletions, and insertions, or splicing mutations ([Table 1](#T1){ref-type="table"} and [Fig. 1](#F1){ref-type="fig"}).

In this study, we describe several novel variants in *CYP19A1*. A homozygote splice-site deletion in the *CYP19A1* gene was found in an African 46,XX neonate presenting with typical clinical manifestations during pregnancy and at birth. An indel variant in exon 5, together with the c.--41C\>T variant in the *CYP19A1* promoter that had been described earlier, was found in an Indian 46,XX child presenting with an unsolved disorder of sex development at age 3 years. Novel point variants were identified in 2 more unrelated adolescent girls in India who presented with poor breast development and polycystic ovaries. To address the impact of the novel *CYP19A1* variants manifesting at different time points of sex development and originating from diverse populations, we performed genetic, functional, and structural studies and compared the findings of novel variants in the *CYP19A1* gene with the published literature.

1. Case Reports, Materials, and Methods {#s1}
=======================================

A. Case Reports {#s2}
---------------

*Family 1.* An 8-day-old newborn was referred to the clinic of A.L. for assessment of ambiguous genitalia. The infant was the seventh child of second-degree consanguineous African parents. The first child was stillborn ([Fig. 2](#F2){ref-type="fig"}). There was maternal virilization during the second pregnancy and the newborn who was declared "male," died on the first day of life (with no further details available). After delivery, signs of virilization slowly decreased in the mother, and she subsequently gave birth to 4 healthy sons without suffering from virilization again during these pregnancies. However, during the seventh pregnancy, the mother, age 36 years, again developed progressive signs of virilization from 12th week of gestation, with facial and abdominal hirsutism, facial acne, clitoral hypertrophy, and deepening of the voice. No drugs or environmental toxins were suspected of influencing the pregnancy. Biochemical workup of the mother revealed marked hyperandrogenism with high testosterone levels (eg, 45.1 nmol/L at 32/40 weeks of pregnancy, normal range is 2.2-10.7 nmol/L). Ultrasound and magnetic resonance imaging studies after delivery revealed enlarged ovaries containing multiple follicles consistent with polycystic ovaries. However, the signs of virilization decreased slowly after birth, and serum testosterone levels normalized within 1 month.

![Genetic characterization of 4 patients harboring novel *CYP19A1* variants. A, Family pedigrees show consanguinity in 3 families. B, Diagram showing localization and specific variations in the *CYP19A1* gene with respect to exon-intron boundaries. Black-filled exon rectangles show exons that are translated into RNA/protein sequences despite the genetic variations.](bvaa030f0002){#F2}

The baby was born at term by spontaneous vaginal delivery. Birth weight, length, and head circumference were normal (3500 g/50 cm/35 cm). Neonatal adaptation was also normal, but the baby had ambiguous genitalia without presenting other dysmorphic features. Genital examination showed a 1.5 cm cliterophallus with a single meatus opening at the base of the genital tubercle and a complete posterior labial fusion (Prader IV). The genital folds were scrotalized, and no gonads were palpable ([Fig. 3](#F3){ref-type="fig"}). Pelvic ultrasound showed a uterus, whereas the gonads were not visible. Karyotype was 46,XX. Biochemical workup revealed normal electrolytes, 17α-hydroxyprogesterone, cortisol, and renin levels, ruling out classic 21-hydroxylase deficiency with congenital adrenal hyperplasia (CAH) ([Table 2](#T2){ref-type="table"}). Testosterone levels were slightly elevated at birth but decreased to normal levels by 1 month, whereas other androgen levels were within reference ranges. Estradiol levels were very low ([Table 2](#T2){ref-type="table"}). Follow-up revealed that the patient did not have any distress as seen in cortisol deficiency. Thus virilization of the 46,XX baby with concurrent virilization of the mother during pregnancy suggested aromatase deficiency in the child.

![Phenotype of girls with *CYP19A1* mutations. A, Picture of the ambiguous genitalia at birth found in the 46,XX disorder of sex development index patient 1. Note the phallus-like tubercle with a single meatus opening at the base and the complete labioscrotal fusion (Prader IV). The photograph is shown with the permission of the parents. B, Magnetic resonance imaging of the pelvis in patient 4 at age 14 years showing a large, multiloculated, cystic mass (6.8 × 9.6 × 6.5 cm) involving bilateral adnexa (\*), displacing the uterus (\#) anteriorly and inferiorly. Few of the cysts are showing hemorrhage. Both ovaries cannot be separately visualized.](bvaa030f0003){#F3}

###### 

Clinical and biochemical characteristics of four 46,XX patients with aromatase deficiency

                                                                                                                   Laboratory Findings                                                                          
  --- --------- ------- -------------------- -------------------- ---------- ------------------------------------- --------------------- ---------- ---------- ---------- ---------- --------------- ---------- -----------
  1   African   Yes     Birth                Prader IV            NA         NK                                    **3.41**                                    **55.9**                                         
                        10 d                                                                                       **2.03**              **1.34**   **4.85**   11.92      504                                   
                        1 mo                                                                                       0.19                  **0.35**   0.8        3.85       305        \< 18                      
                        4 mo (minipuberty)                                                                         **0.38**                                    1.04                                             
  2   Indian    No      Birth                Atypical genitalia   NA                                                                                                                                            
                        3 y                  Prader IV            NA         See Figure 3.                         \< 0.45                                     5          745^*a*^   NM              \< 1       **12**
  3   Indian    Maybe   14 y                 Clitoromegaly        B3/P4/A3   Polycystic ovaries, ovarian torsion   **2.06**              1.93                  2.03       648^*a*^   58.7            **39.9**   **10.98**
  4   Indian    Yes     14 y                 Clitoromegaly        B3/P4/A3   Polycystic ovaries                    **2.6**               3.58                  1.38       634^*a*^   **\<** **18**   **32**     **37**

Laboratory values outside the normative range are shown in bold.

Abbreviations: 4A, androstenedione; 17OHP, 17α-hydroxyprogesterone; DHEAS, dehydroepiandrosterone-sulfate; E2, estradiol; FSH, follicle-stimulating hormone; LH, luteinizing hormone; NA, not applicable; NK, not known; NM, not measurable; Pt, patient; T, testosterone.

^*a*^Adrenocorticotropin-stimulated 60-minute values.

*Patient 2.* This 46,XX infant was referred to the clinic of V.P.P. for workup of ambiguous genitalia at age 3 years. She was the only child of nonconsanguineous Indian parents and was noted to have a phallic structure with absent gonads at birth. There was no history of maternal virilization or hirsutism during pregnancy. Evaluation elsewhere had ruled out CAH. Karyotype was 46,XX, and laparoscopy had been performed at age 8 months and revealed a uterus and fallopian tubes. Unilateral gonad biopsy was suggestive of ovarian tissue. At age 3 years, she presented with a well-formed phallus with a single opening at the tip with good prepucial skin and fused labioscrotal folds with rugosity (Prader IV). Gonads were not palpable. Biochemical workup revealed normal cortisol response to an adrenocorticotropin stimulation test (60 minutes, 745 nmol/L), normal 17-hydroxyprogesterone, undetectable testosterone, elevated follicle-stimulating hormone (FSH), and prepubertal luteinizing hormone (LH) ([Table 2](#T2){ref-type="table"}). A 100 cell count karyotype was repeated, which again revealed only 46,XX cell lines. Laparoscopy was also repeated and confirmed earlier findings; gonadal biopsy from the other side revealed primordial follicles with ovarian stroma. Because of normal stimulated serum cortisol and 17-hydroxyprogesterone, P450 oxidoreductase deficiency (PORD) was considered less likely and aromatase deficiency was suspected.

*Patient 3.* Patient 3, from India, presented at age 14 years with an acute abdomen due to ovarian torsion. She was the second child of consanguineous parents ([Fig. 2](#F2){ref-type="fig"}). Past medical history was suggestive for some maternal virilization during pregnancy, but at birth, the girl was recorded to be healthy, although retrospectively the prominence of the clitoris was present since birth. Pubertal development started at around age 11 years with pubic and axillary hair, and voice change was noted; breast development started after age 12.5 years, and growth of facial hair in the past 6 months was noted. Physical exam revealed a weight of 40.6 kg (P10), height 160 cm (P50), blood pressure 90/50 mm Hg, Ferriman Gallway Score 4, and Tanner stage B3/P4/A3. Exam of the external genitalia revealed a slightly enlarged clitoris (\> 1 cm). Biochemical workup showed elevated LH, FSH, and testosterone with rather low estradiol ([Table 2](#T2){ref-type="table"}). Ultrasound and laparoscopy revealed polycystic ovaries on both sides with torsion of the left ovary.

*Patient 4.* Patient 4, from India, born to consanguineous parents, presented at age 14 years for abdominal pain and oligomenorrhea. No maternal virilization was reported during pregnancy. The girl likely had atypical genitalia at birth, but this was not recorded. Pubertal development started at around age 10 to 11 years with menarche at around 12 years. Breast development was poor, and clitoromegaly was claimed. At presentation, her weight was 50 kg (P50), height 155 cm (P25), and blood pressure was 90/60 mm Hg. No skeletal anomalies were found, and Tanner stage was B3P4A3. The genital exam showed a clitoromegaly of 20 mm, a common urogenital sinus, and posterior labial fusion. Ultrasound and magnetic resonance imaging revealed enlarged polycystic ovaries ([Fig. 3](#F3){ref-type="fig"}). Laboratory findings were abnormal for elevated LH, FSH, and testosterone, whereas estradiol was not detectable ([Table 2](#T2){ref-type="table"}).

B. Genetic Studies {#s3}
------------------

Genetic studies of rare steroid disorders were approved by the cantonal ethics' commission of Bern, Switzerland. Written informed consent for the genetic studies was obtained from parents and teenage minors. DNA was extracted from blood samples of the patient and both parents as available. The *CYP19A1* gene (NM_000103.3 or NG_007982.1) was sequenced from genomic DNA using a candidate exon-by-exon approach, as previously described \[[@CIT0001]\]. Additional primers were used to characterize the deletion found at the boundary of exon/intron 9 and the deletion/insertion in exon 5; these primer sequences are available on request.

For the minigene experiment for genetic workup of patient 1, the wild-type (wt) and variant genomic *CYP19A1* sequence comprising exon 9 to exon 10 -- 3'UTR was cloned in a pcDNA3.1 vector. These vectors were then transiently transfected in HEK293 cells using Lipofectamine 2000 (Invitrogen AG, Life Technologies). Forty-eight hours after transfection, total RNA was extracted and reverse transcribed. Finally, transcripts of wt and variant vectors were polymerase chain reaction amplified. Polymerase chain reaction products were run on an agarose gel and visualized, as well as subjected to direct sequencing (Microsynth AG).

C. Analysis of Conservation of Amino Acids of CYP19A1 {#s4}
-----------------------------------------------------

We used ConSurf analysis to study the evolutionary conservation of amino acids (aa) in CYP19A1 based on structural and phylogenetic relationships between the sequences from different species \[[@CIT0046], [@CIT0047]\]. All CYP19A1 sequences in the Uniprot database were searched, and the best quality sequences based on 3 rounds of iterated Phi-BLAST search were kept for further analysis. Multiple-sequence alignment of selected sequences was made to compare the position of variants described in this report with aa located at those positions in different species ([Figs. 4](#F4){ref-type="fig"} and [5](#F5){ref-type="fig"}).

![Multiple sequence alignment of affected CYP19A1 amino acid sequences from patients showing that all variants described in this report are conserved in higher primates. The valine 161 residue is well conserved across species and in some cases, a similar amino acid (isoleucine) was found (alligator, manakin, and turtle). The CYP19A1 proteins from human, chimpanzee, rhesus monkey and pig have an arginine at the position 264, whereas dog, cow, and mouse have a histidine, and rat, American alligator, golden-collared manakin, and turtle have glutamine at amino acid position 264. Considering the critical role of arginine 375 in heme binding, it was found to be conserved across species and no substitutions were identified in all the CYP19A1 sequences analyzed.](bvaa030f0004){#F4}

![Multiple sequence alignment of CYP19A1 amino acid sequences from patients is shown. All the variants described in this report are conserved in higher primates as shown in [Fig. 4](#F4){ref-type="fig"}.](bvaa030f0005){#F5}

D. CYP19A1 Protein Structure Modeling {#s5}
-------------------------------------

*In silico* mutagenesis of the 3-dimensional protein models of CYP19A1, according to the variations identified in the patients, were performed as described earlier \[[@CIT0001]\] using the 3- dimensional x-ray crystal structure of human aromatase (3S79) obtained from the Protein Data Bank database \[[@CIT0048]\]. Model building was performed with programs YASARA \[[@CIT0049]\] and WHATIF \[[@CIT0050]\]. A screening of rotamer libraries was used to minimize stearic clashes with the neighboring residues that resulted from the substitution of aa. Molecular dynamics (MD) simulations were used to optimize the aa side chains. The final model was refined by a 1000 ps MD simulation using the AMBER ff15ipq forcefield \[[@CIT0051]\]. Structure models were drawn using the software Pymol ([www.pymol.org](http://www.pymol.org)), and rendering of images was performed with POVRAY ([www.povray.org](http://www.povray.org)).

E. Predicting the Effect of Protein Stability Using Site-Directed Mutator {#s6}
-------------------------------------------------------------------------

The site-directed mutator (SDM) tool \[[@CIT0052]\] described by Topham and colleagues \[[@CIT0053]\] was used for predicting the effect of *CYP19A1* variants. SDM software uses environment-specific substitution frequencies within homologous protein families to calculate a stability score. The structures of variants used for analysis were generated using the built-in program ANDANTE \[[@CIT0054]\]. SDM provides a pseudo-δ G score for stability prediction and also a potential impact of genetic variants for causing disease.

F. In vitro Functional Testing of CYP19A1 Variants {#s7}
--------------------------------------------------

The human wt *CYP19A1* complementary DNA (cDNA) expression vector was described previously \[[@CIT0001]\]. The new deletion constructs were created according to the cDNA sequences identified by the genetic analysis and minigene experiments. For point mutations, site-directed mutagenesis was performed to obtain the specific cDNA variants. HEK293 cells were transiently transfected with wt and variant CYP19A1 vectors for 48 hours (Lipofectamine 2000). Aromatase activity was then measured by the tritiated water release assay using cold/hot androstenedione as substrate (10 nM/\[1β-^3^H(N)\]-androstene-3,17-dione; 20 000 cpm/well) as previously reported \[[@CIT0001], [@CIT0055]\]. Data represent the mean ± SD of 3 independent experiments performed in duplicate. The student t test was used to test the significance (*P* ≤ .05).

G. Tissue Histology Studies {#s8}
---------------------------

Formalin-embedded tissue biopsy material obtained by laparoscopy of patient 2 (see "Case Reports") was available for histology studies. Tissue was investigated microscopically after hematoxylin and eosin staining. Tissue was compared to ovarian tissues originating from one representative, age-matched normal girl, and one girl with Turner syndrome (TS).

2. Results {#s9}
==========

A. Phenotype-Genotype Characterization {#s10}
--------------------------------------

We found novel *CYP19A1* variants in 4 girls ([Fig. 2](#F2){ref-type="fig"}) manifesting either at birth with atypical genitalia or puberty with poor breast development, clitoromegaly, abnormal menstrual bleeding, polycystic ovaries, and ovarian torsion ([Fig. 3](#F3){ref-type="fig"}). Three mothers had signs of virilization during pregnancy ([Table 2](#T2){ref-type="table"}). Biochemical analysis revealed elevated androgens during pregnancy and in the neonate (in family 1), and in the adolescent girls with incomplete pubertal development (patients 3 and 4). Gonadotropins LH and FSH were elevated in the pubertal girls, whereas FSH was also abnormally high in the 3-year-old ([Table 2](#T2){ref-type="table"}). CAH due to 21-hydroxylase (and PORD) was ruled out by normal serum cortisol and 17-hydroxyprogesterone levels (after adrenocorticotropin stimulation) in all patients, and with urinary steroid profiling on spot urine by gas chromatography--mass spectrometry in patient 2 (data not shown) \[[@CIT0056]\].

Genetic analysis of patient 1 revealed a homozygote splice site deletion at the exon-intron 9-3' boundary ([Fig. 2](#F2){ref-type="fig"}). Both consanguineous parents were heterozygote carriers of this variant. The 4 healthy brothers were not available for analysis. Characterization of this novel variant by minigene experiments revealed that the coded transcript contained the wt *CYP19A1* sequence from exon 2 to exon 9, but then found a stop codon within intron 9 after addition of 6 aa due to the intronic splice site deletion that prevented correct splicing. The corresponding protein p.423_503del therefore lacked exon 10 completely and was only 426 aa long compared to 503 aa of the wt protein.

In patient 2, compound heterozygote variants of the *CYP19A1* gene were found. The previously described promoter c.--41C\>T variant and a novel deletion/insertion in exon 5 at c.603_608 led to a truncated aromatase protein that was predicted to have no enzyme activity (p.P154_delins) (25). Both parents were carriers of the p.P154_delins variant, and the mother carried, in addition, the c-41C\>T variant ([Fig. 2](#F2){ref-type="fig"}). Other family members were phenotypically normal and not available for genetic studies.

Patient 3 had 2 point mutations in exons 5 and 7, corresponding to c.624T\>A (p.V161D) and c.932C\>T (p.R264C) together with the promoter variant c.--41C\>T. The consanguineous parents carried all these variants on 1 allele. Siblings were not affected and were not available for our study.

Finally, a homozygote point mutation in exon 9 was found in patient 4, c.1265C\>T, p.R375C. Of the consanguineous parents, only the mother's DNA was available for genetic analysis. She was found to carry the variant on 1 allele ([Fig. 2](#F2){ref-type="fig"}).

B. Bioinformatic Characterization of the CYP19A1 Variants {#s11}
---------------------------------------------------------

Multiple-sequence alignment of affected CYP19A1 aa sequences from the patients is shown in [Fig. 5](#F5){ref-type="fig"}. All mutations described in this report are conserved in higher primates ([Fig. 4](#F4){ref-type="fig"}). An analysis of different aromatase sequences across species revealed valine 161 is well conserved across species, and in some cases, a similar aa (isoleucine) was found (alligator, manakin, and turtle). The V161D replacement was predicted to be less stable compared to wt CYP19A1, with a δ G value of --2.5 compared to wt protein. The substitution of valine 161 for an aspartate introduces a buried charge and a hydrophilic residue in the core of the protein, which would cause reduced stability. Further, the helix 144 to 165 is also involved in protein stabilization, and the introduction of a charged residue is likely to cause reduced flexibility ([Fig. 6A](#F6){ref-type="fig"}).

![Structural location of CYP19A1 variants. A, Point mutations. Here a ribbons model of CYP19A1 protein colored in the rainbow from amino terminus (violet) to carboxy terminus (red) is shown and the bound substrate, androstenedione, and central heme molecule are depicted as stick models. Heme is ligated to the protein via cysteine 437 residue and forms the catalytic center of the CYP19A1 protein. The substitution of valine 161 for aspartate introduces a buried charge and a hydrophilic residue in the core of the protein, which would cause reduced stability of the structure. The R264 residue on aromatase is surface exposed and located on the G helix of the CYP19A1 structure, which is part of the substrate access channel, and it has been widely reported to be flexible in cytochromes P450. The R375 residue is involved in binding of heme propionate at the catalytic center of the CYP19A1, and its change to cysteine will lead to loss of heme binding and a nonfunctional protein. B, Identified deletion/insertion variations. The P423_H503delins mutation results in loss of critical amino acids in aromatase, including the heme ligating cysteine 437, and would, therefore, result in an inactive enzyme that would also be unstable and subject to degradation.](bvaa030f0006){#F6}

R264C (rs700519) is a common polymorphic variant of CYP19A1 (CYP19A1\*4). The R264C variant of CYP19A1 is present at a lower frequency in the European population, with a minor allele frequency (MAF) of 0.02 in the 1000 Genomes database but is more prevalent in the East Asian (MAF 0.17), South East Asian (MAF 0.24) and African (MAF 0.18) populations. The R264 residue on the aromatase is on the surface and located on the G helix of the CYP19A1 structure ([Fig. 6A](#F6){ref-type="fig"}), which is part of the substrate access channel, and it has been widely reported to be flexible in cytochrome P450 proteins. The R264 residue is also the central residue of a 3-arginine cluster that is part of a consensus sequence for several kinases. Therefore, R264 may have a role both in the regulation of substrate access and posttranslational modifications of aromatase. Compared to the R263 position in aromatase, the R264 position is variable among species. The human, chimpanzee, rhesus monkey and pig have an arginine at the position 264; dog, cow, and mouse have a histidine, whereas the rat, American alligator, golden-collared manakin, and turtle have glutamine at position 264. As part of the KRRR sequence (AA 262-265), lysine 262 and arginine 263 are conserved across species and no variations were found at these positions, and at position 265, either arginine or lysine is present across species ([Fig. 4](#F4){ref-type="fig"}).

The R375 residue is involved in binding of heme propionate at the catalytic center of the CYP19A1, and its change to cysteine will lead to loss of heme binding, resulting in a nonfunctional protein, which is consistent with a complete loss of activity observed for this mutation ([Figs. 6A](#F6){ref-type="fig"} and [7](#F7){ref-type="fig"}). Considering the critical role of arginine 375 in heme binding, it was found to be conserved across species, and no substitutions were identified in all CYP19A1 sequences analyzed ([Fig. 4](#F4){ref-type="fig"}).

![Critical role of arginine 375 in heme binding. A and B, Structures of A, wild-type (WT), and B, R375C aromatase, shown as a ribbons model. The R375 residue is essential for the binding of heme at the catalytic center of the A, CYP19A1, and its change to B, cysteine, will lead to loss of heme binding, resulting in a nonfunctional protein. A complete loss of activity was observed for the R375C variant. Therefore, the arginine 375 residue has a critical role in heme binding and activity of aromatase. These observations are further substantiated by the conservation of R375 residue in aromatase across species, and no substitutions were identified in all CYP19A1 sequences analyzed ([Fig. 4](#F4){ref-type="fig"}). C and D, A close-up of heme ligation in aromatase C, WT and D, R375C. D, After the change of arginine 375 to cysteine, one of the bonds holding the heme in place, formed between the propionate group in heme and arginine 375, is disrupted. The heme in aromatase, similar to other cytochrome P450 proteins, is held together by several bonds between the propionates of heme and arginines or histidine/tryptophan groups located at the catalytic center. Disruption of these linkages will lead to an unstable heme-binding site in aromatase and loss of heme, which would cause a nonfunctional protein. All the critical arginines (115, 145, and 375), as well as tryptophan 141 and cysteine 427, are conserved across species ([Fig. 4](#F4){ref-type="fig"}), and no variation is observed at any of these places, confirming the importance of these amino acids in the function of aromatase.](bvaa030f0007){#F7}

The P154delins variant results in a truncated protein, which would be degraded ([Fig. 8](#F8){ref-type="fig"}). The P423_H503delins mutation results in the loss of critical aa in aromatase, including the heme-ligating cysteine 437 ([Fig. 6B](#F6){ref-type="fig"}), and would, therefore, result in an inactive enzyme that would also be unstable and subject to degradation.

![The P154delIns protein variant lacks most of the critical residues of aromatase required for catalytic function because of truncation (shown in magenta). Such a small protein, without functionally important structural features, will be misfolded and degraded, leading to a complete loss of aromatase activity.](bvaa030f0008){#F8}

C. In vitro Functional Characterization of the Identified CYP19A1 Variants {#s12}
--------------------------------------------------------------------------

All *CYP19A1* variants were tested in HEK293 cells for their ability to convert androstenedione to estrone using the tritiated water-release assay, as previously described \[[@CIT0001], [@CIT0057]\]. Both deletion/insertion variants and the 2 point variants p.V161D and p.R375C showed complete loss of aromatase activity ([Fig. 9](#F9){ref-type="fig"}). By contrast, the p.R264C variation had similar aromatase activity as the wt CYP19A1. The double variant p.V161D and p.R264C, however, showed complete loss of function, like the p.V161D single variant. The functional effect of the promoter variant c.--41C\>T on *CYP19A1* expression has been previously described \[[@CIT0025]\].

![Aromatase activity of identified *CYP19A1* variants. Variants were built into the mammalian expression vector containing wt *CYP19A1* cDNA. HEK293 cells were transiently transfected with wt and variant CYP19A1 plasmids, and aromatase activity was assessed by the tritiated water-release assay testing conversion of androstenedione to estrone. Compared to wt, all variants except p.R264C showed complete loss of activity. \**P* value is less than or equal to .05.](bvaa030f0009){#F9}

D. Histological Description of an Aromatase-Deficient Ovary in Infancy {#s13}
----------------------------------------------------------------------

Ovarian tissue for histological evaluation was available from patient 2. At age 3 years, histology showed a normal-appearing ovary with normal-looking stroma and follicles on one side ([Fig. 10A](#F10){ref-type="fig"}) compared to a healthy control ovary of the same age ([Fig. 10C](#F10){ref-type="fig"}). By contrast, on the contralateral side, a streak gonad was identified macroscopically, with histological ovarian-like stroma without follicles ([Fig. 10B](#F10){ref-type="fig"}) as found in typical TS (see age-matched picture of TS in [Fig. 10D](#F10){ref-type="fig"}).

![Histology of an ovary originating from a toddler with aromatase deficiency. A, Hematoxylin and eosin (HE) histology picture of one ovary of patient 2 showing a normal ovary with normal stroma and follicles. B, HE histology of the contralateral ovary showing a streak gonad without follicles. C, HE picture of a normal, age-matched ovary. D, HE picture of a typical Turner syndrome streak ovary, age matched.](bvaa030f0010){#F10}

3. Discussion and Conclusion {#s14}
============================

There are only a few inborn errors of steroidogenesis that cause virilization of 46,XX individuals. The first group of disorders causes not only sex hormone disturbances but also glucocorticoid deficiency, and is therefore called *CAH*. This group comprises 3β-hydroxysteroid dehydrogenase (HSD3B2), 21-hydroxylase (CYP21A2), and 11-hydroxylase (CYP11B1) deficiencies. The second group with normal glucocorticoid production comprises aromatase deficiency (CYP19A1) and PORD, although in PORD stimulated cortisol production is often also compromised \[[@CIT0056], [@CIT0058]\]. Furthermore, mothers virilize during pregnancy only with disorders of the second group, which affect the aromatization of fetal androgens by the fetal-placental unit.

All girls with CYP19A1 deficiency reported in this study had normal cortisol production but suffered from androgen excess that manifested in utero (in 3 out of 4), at birth (in 2 to 3 out of 4), or puberty (in 1 or 2 out of 4) (see [Table 2](#T2){ref-type="table"}). Whether a detailed examination of the external genitalia would have revealed some atypical findings in patient 3 at birth remains speculative. So far, most reported 46,XX individuals with aromatase deficiency manifested at birth with moderate to severe virilization of the external genitalia (Prader III-V) (n = 25/34; [Table 1](#T1){ref-type="table"}). This has led to male sex assignment at birth in three 46,XX individuals, 2 of whom were reassigned to the female sex after diagnosis in childhood. Signs of virilization during pregnancy have been described in about half of mothers carrying an affected child. During infancy and childhood, ovarian cysts were noted in several and were either symptomatic or seen by imaging studies. At puberty, incomplete development with poor breast development, menstrual cycle anomalies, polycystic ovaries, and signs of androgen excess (eg, hirsutism, acne, enlarged clitoris) are typically due to estrogen deficiency and elevated androgens. Late diagnosis at pubertal age is described in less than one-third of reported 46,XX aromatase-deficient female patients. Of the 15 reported female individuals older than pubertal age, 4 showed no signs of spontaneous puberty, 6 had incomplete development, and only 5 spontaneously reached Tanner 5 ([Table 1](#T1){ref-type="table"}).

By contrast, affected 46,XY individuals typically present at around age 20 to 30 years with extremely tall stature due to failure of growth arrest. Only if the diagnosis is known in the family or maternal virilization during pregnancy raised suspicion, may diagnosis be made earlier in boys. We also suspect that the diagnosis is less often made in boys than girls because the clinical picture is less remarkable and manifests only in early adulthood when genetic disorders are less suspected; this may be evidenced by fewer reported cases of male patients in the literature (n = 13/47; [Table 1](#T1){ref-type="table"}), which does not reflect the autosomal recessive inheritance and the true incidence.

Owing to enlarged ovaries with cysts or polycystic ovaries, torsion of an ovary is a frequent complication that may occur early in life. This complication can be prevented by very low-dose estrogen replacement starting early in life \[[@CIT0034], [@CIT0059]\]. At puberty, sex hormone replacement therapy is required to allow for complete pubertal development and normal menstrual bleeding. So far no successful pregnancy has been described in a woman with aromatase deficiency. However, it is not excluded that this could be possible with the help of assisted reproduction, as recently demonstrated in a woman with 17-hydroxylase (CYP17A1) deficiency, a steroid enzyme essential for the production of all sex hormones \[[@CIT0060]\]. Histologic investigations of ovarian tissue of female patients carrying *CYP19A1* variants are scarce. We had a chance to investigate ovarian biopsy material in patient 2 and found a normal-looking ovary on one side and a streak gonad on the other. In the literature, ovaries are often reported to look normal or only slightly abnormal in size by imaging studies in very young girls, although smaller cysts may be found very early when specifically searched for. Imaging studies later during infancy and childhood mostly reveal abnormal ovarian cysts, which may resemble the picture of a polycystic ovary by the age of puberty ([Table 1](#T1){ref-type="table"}). This resulted in ovarian torsion in several cases, even at a very young age.

Furthermore, streak ovaries or absent/nonvisualized ovaries have been reported with *CYP19A1* deficiency \[[@CIT0017], [@CIT0027], [@CIT0030]\]. Thus it appears that aromatase deficiency might lead to an earlier destruction of the ovary than with other steroid biosynthetic disorders such as lipoid CAH due to steroidogenic acute regulatory protein deficiency. In STAR deficiency, lipid overload destroys the gonad over time and a PCOS-like phenotype is not characteristic \[[@CIT0061]\]. Studies of ovary development have shown that concerted activity of aromatase (as well as other steroidogenic enzymes such as HSD17s and HSD3B2), steroid hormones (eg, estrogens and progesterone), and gonadotropins (eg, FSH) is essential for normal primordial follicle pool development during fetal life as well as for normal follicle maturation and ovulation in the adult ovary \[[@CIT0062]\]. In the human fetal ovaries, expression of aromatase and estrogen receptors is upregulated in the second trimester when primordial folliculogenesis is fully active \[[@CIT0063]\]. By contrast, mice lacking aromatase activity develop ovaries with diminished oocyte density \[[@CIT0064], [@CIT0065]\]. In addition, coordinated action of estrogens and FSH are also crucial for the proper timing of folliculogenesis \[[@CIT0066]\]. In aromatase deficiency lack of estrogens results in abnormal gonadotropin feedback, which affects follicle growth in the ovaries. It has been shown that for the formation of (poly-)cystic ovaries elevated FSH plays a critical role \[[@CIT0067], [@CIT0068]\]. Overall, these facts from the literature may explain the ovarian phenotypes (both streak gonads and polycystic ovaries) seen with aromatase deficiency. Based on this knowledge and clinical experience (eg, \[[@CIT0034]\]) (preventive) treatment of polycystic ovaries with estrogen replacement normalizing FSH should be advised in all patients with aromatase deficiency.

Human *CYP19A1* variants described so far are summarized in [Table 1](#T1){ref-type="table"}. They span over all exons and comprise all types of genetic variations, as shown in [Fig. 1](#F1){ref-type="fig"}. The genotype-phenotype correlation seems doubtful, but structure-function prediction has revealed consistent results with few exceptions. We found novel *CYP19A1* variants in 4 affected girls. These variants were all predicted to severely affect enzyme activity, and functional tests confirmed this prediction. Novel deletion-insertion variants of *CYP19A1* found in patients 1 and 2 received the label "pathogenic" when characterized according to American College of Medical Genetics and Genomics (ACMG) standards and guidelines \[[@CIT0069]\]. *In silico* structure-function studies of the identified *CYP19A1* variations showed loss of the heme-binding site due to the *R375C* variation and was predicted to cause a loss of function. In the case of the *V161D* variant, a loss of protein stability leading to degradation was predicted. This novel point mutation found in patient and family 3 is likely pathogenic according to ACMG characterization and was found in combination with known variants --41C\>T and *R264C*. Variants *R264C* and *R375C* have been described previously \[[@CIT0018], [@CIT0070]\]. In line with our results, *R375C* was found to cause a complete loss of function. Although *in silico* structural prediction could not provide a clear analysis for the *R264C* variant, we found that the *R264C* variant showed activity similar to wt *CYP19A1*. The *R264C* variation is known in the literature as a polymorphism of *CYP19A1*, which seems common in Southeast Asia \[[@CIT0070]\]. However, this *CYP19A1* variant may affect enzyme function when it is present in combination with specific variants of cytochrome P450 oxidoreductase (*POR*), as reported in a recent study \[[@CIT0070]\]. Partial loss of function of aromatase activity has been found with *CYP19A1* variant *R192H* \[[@CIT0001]\] and with several *POR* variants \[[@CIT0056], [@CIT0071]\]. Patients carrying these mutations manifest with variable degrees of virilization either at birth or puberty.

In summary, we describe clinical, genetic, and functional implications of novel *CYP19A1* variants identified in 4 girls originating from Africa and India. CYP19A1 deficiency seems to cause maternal virilization in more than 50% of pregnancies and manifest with some degree of ambiguous genitalia in more than 70% of 46,XX newborns. Additionally, about 80% of affected girls are unable to enter or complete puberty spontaneously and need hormonal replacement therapies. The ovary with aromatase deficiency develops a polycystic ovary phenotype in most cases, but streak gonads are also seen. Normal aromatase activity in concerted action with other steroid enzymes and hormones as well as gonadotropins seem essential for proper ovarian follicle pool development during fetal life and for follicle maturation and ovulation during the reproductive years.
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